Stay updated on Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial page.

Latest updates to the Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial page
- Check2 days agoChange DetectedThe study page now displays a 403 Forbidden message, replacing the study details with an error screen while the site chrome remains visible. This indicates restricted access to the page's primary content.SummaryDifference17%

- Check9 days agoChange DetectedThe page shows an updated revision tag, upgrading from v3.6.6 to v3.7.0 to reflect a content refresh.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedA new page revision tag v3.6.6 was added, replacing the previous v3.6.5, indicating a minor backend/template update.SummaryDifference0.0%

- Check31 days agoChange DetectedThe NIH grant/contract year 2017 was added to the study identifiers. This supplements the existing EudraCT number with funding context for the trial.SummaryDifference0.0%

- Check45 days agoChange DetectedThe page’s footer now displays Revision: v3.6.5, replacing the previous v3.6.4. This indicates a software update or patch applied to the page.SummaryDifference0.0%

- Check59 days agoChange DetectedRevision tag updated from v3.6.3 to v3.6.4, indicating a new release version. This appears to be a minor internal update with no user-facing content changes on the study page.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Epacadostat in Urothelial Carcinoma Clinical Trial page.